司库奇尤单抗治疗伴潜伏性结核感染和乙型肝炎肝硬化的红皮病型银屑病1例并文献复习

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (602 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Due to the selective immunosuppressive effect of biological agents, long-term use in psoriasis patients may lead to reactivation of hepatitis B virus and mycobacterium tuberculosis. Clinical applications have found that Secukinumab is safer than other biological agents. This article retrospectively collected a case of erythrodermic psoriasis patient with latent tuberculosis infection and hepatitis B cirrhosis treated by Secukinumab, who suffered from bilateral femoral head necrosis due to irregular systematic use of hormones. After informed consent, the patient was given anti-hepatitis B virus and preventive antituberculosis treatment. After that, the patient was given the standard protocol of Secukinumab and then bilateral total hip arthroplasty. At the 24th week of treatment, the patient's psoriasis area and severity index (PASI) reached 90; and at the 40th week, the patient reached PASI100, at the 60th week of treatment, the patient still reached PSAI90, with only the scaly erythema scattered in front of both tibia. Up to now, no hepatitis B virus replication and active tuberculosis have been found during follow-up. Through the introduction of this case and review of relevant literature, this article shows the effectiveness and safety of Secukinumab, and promote dermatologists' awareness of biological agents in improvement of metabolic comorbidity, hoping to make more patients with psoriasis accompanied by hepatitis B and tuberculosis obtain better clinical prognosis.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2024/V31/I1/150

[1]	Reynolds KA，Pithadia DJ，Lee EB，et al.A systematic review of treatment strategies for erythrodermic psoriasis[J].J Dermatolog Treat，2021，32（1）：49-55.
[2]	Galluzzo M，D'Adamio S，Campione E，et al.A clinical case of severe disease burden：an erythrodermic psoriatic patient treated with secukinumab[J].J Dermatolog Treat，2018，26：1-11.
[3]	Weng HJ，Wang TS，Tsai TF.Clinical experience of secukinumab in the treatment of erythrodermic psoriasis：a case series[J].Br J Dermatol，2018，178（6）：1439-1440.
[4]	Singh RK，Lee KM，Ucmak D，et al.Erythrodermic psoriasis：pathophysiology and current treatment perspectives[J].Psoriasis（Auckl），2016，6（3）：93-104.
[5]	Rendon A，Schs■kel K.Psoriasis pathogenesis and treatment[J].Int J Mol Sci，2019，20（6）：1475.
[6]	Matsuzaki G，Umemura M.Interleukin-17 family cytokines in protective immunity against infections：role of hematopoietic cell－derived and non－hematopoietic cell－derived interleukin-17s[J].Microbiol Immunol，2018，62（1）：1-13.
[7]	Xing X，Liang Y，Sarkar M，et al.IL-17 responses are the dominant inflammatory signal linking inverse，erythrodermic and chronic plaque psoriasis[J].J Invest Dermatol，2016，136（12）：2498-2501.
[8]	Mugheddu C，Atzori L，Lappi A，et al.Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis[J].J Eur Acad Dermatol Venereol，2017，31（9）：e420-e421.
[9]	Mateu-Puchades A，Santos-Alarcón S，Martorell-Calatayud A，et al.Erythrodermic psoriasis and secukinumab：Our clinical experience[J].Dermatol Ther，2018，31（4）：e12607.
[10]	朱慧英，施仲香，曹楠，等.司库奇尤单抗治疗红皮病型银屑病一例并文献复习[J].中国麻风皮肤病杂志，2021， 37（10）：653-656.
[11]	刘洛辰，刘小菡，张红婧，等.司库奇尤单抗治疗红皮病型银屑病2例[J].中国皮肤性病学杂志，2021，35（1）：116-117.
[12]	张婷婷，朱凤仪，杨梅，等.司库奇尤单抗治疗红皮病型银屑病7例的临床疗效及安全性观察[J].中华皮肤科杂志，2022，55（3）：234-236.
[13]	Sivamani RK，Goodarzi H，Garcia MS，et al.Biologic therapies in the treatment of psoriasis：a comprehensive evidencebased basic science and clinical review and a practical guide to tuberculosis monitoring[J].Clin Rev Allergy Immunol，2013， 44（2）：121-140.
[14]	Fowler E，Ghamrawi RI，Ghiam N，et al.Risk of tuberculosis reactivation during interleulin-17 inhibitor therapy for psoriasis：a systematic review[J].J Eur Acad Dermatol Venereol，2020，34（7）：1449-1456.
[15]	孙春雷.合并乙肝或结核的银屑病患者使用生物制剂的安全性及疗效分析[D].长春：吉林大学白求恩医学院，2022：35-37.
[16]	Mrowietz U，Riedl E，Winkler S，et al.NO reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab：A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis[J].J Am Acad Dermatol，2020，83（5）：1436-1439.
[17]	Anton C，Machado F，Ramirez J，et al.Latent tuberculosis infection in patients with rheumatic diseases[J].J Bras Pneumol，2019，45（2）：e20190023.
[18]	Cantini F，Nannini C，Niccoli L，et al.Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice[J].Autoimmun Rev，2015，14（6）：503-509.
[19]	Deodhar A，Mease PJ，McInnes IB，et al.Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis，psoriatic arthritis，and ankylosing spondylitis：integrated pooled clinical trial and post-marketing surveillance data[J].Arthritis Res Ther，2019，21（1）：111.
[20]	Gui XY，Yu XL，Jin HZ，et al.Prevalence of Metabolic Syndrome in Chinese Psoriasis Patients：A Hospital-Based Cross-Sectional Study[J].J Diabetes Investig，2018，9（1）：39-43.
[21]	应洁雅，相文忠，宋秀祖，等.代谢综合征与皮肤病[J].中华皮肤科杂志，2022，54（7）：642-645.
[22]	Pizzatti L，Mugheddu C，Sanna S，et al.Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab[J].Dermatol Ther，2020，33（3）：e13348.